What is the role of FDG-PET in thoracic oncology in 2010?

18F-Fluorodeoxyglucose-Positron Emission Tomography (FGD-PET) has been considered to have a major impact on the management of lung malignancies since the beginning of this century. Its value has been demonstrated by many publications, meta-analysis and European/American/Japanese recommendations. PET...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Revue de pneumologie clinique 2010-09, Vol.66 (4), p.221-238
Hauptverfasser:	Vaylet, F, Margery, J, Bonardel, G, Le Floch, H, Rivière, F, Gontier, E, Ngampolo, I, Mairovitz, A, Marotel, C, Foehrenbach, H
Format:	Artikel
Sprache:	fre
Schlagworte:	Fluorodeoxyglucose F18 Humans Lung Neoplasms - diagnostic imaging Lung Neoplasms - pathology Neoplasm Staging Positron-Emission Tomography - methods Predictive Value of Tests Radiopharmaceuticals Sensitivity and Specificity Tomography, X-Ray Computed
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	18F-Fluorodeoxyglucose-Positron Emission Tomography (FGD-PET) has been considered to have a major impact on the management of lung malignancies since the beginning of this century. Its value has been demonstrated by many publications, meta-analysis and European/American/Japanese recommendations. PET combined with computed tomography has provided useful information regarding the diagnosis and staging of lung cancer and allows for the delivery of adaptive radiotherapy. In its more common uses, PET has been shown to be cost-effective. With the widespread use of new radiotracers, PET will play an increasing role in the evaluation of response to treatment.
ISSN:	0761-8417
DOI:	10.1016/j.pneumo.2010.07.010